ALLERGY THERAPEUTICS PLC

Director's Dealing • Mar 26, 2021

National Storage Mechanism | Additional information

RNS Number : 7037T

Allergy Therapeutics PLC

26 March 2021

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Pledge of Shares

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that today, it was notified that Manuel, Llobet, Chief Executive Officer and PDMR, entered into a personal loan agreement whereby security over 600,000 ordinary shares of 0.01 pence each in the capital of the Company was granted in favour of Banco Santander.

There is no change in Mr Llobet's beneficial shareholding in the Company and he continues to have an interest and voting rights in 3,325,000 ordinary shares representing approximately 0.52% of the issued share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Manuel Llobet

2

Reason for the notification

a)

Position/status

Manuel Llobet - Chief Executive Office and PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ALLERGY THERAPEUTICS PLC

b)

LEI

LEIR97215202003301009534776

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares

b)

Identification code

GB00B02LCQ05

c)

Nature of the transaction

Mr Llobet entered into a personal loan agreement with Banco Santander whereby security over 600,000 ordinary shares in the Company.  Mr Llobet remains the beneficial owner of the shares subject to the pledge and retains full voting rights. 

d)

Price(s) and volume(s)

Price(s)	Volume(s)
n/a	600,000

e)

Aggregated information  

n/a

f)

Date of the transaction

26 March 2021

g)

Place of the transaction

Outside a trading venue

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Erik Anderson, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser

allergytherapeutics@consilium-comms.com

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFZGZFVVNGMZM